RUNX1: A Potential Drug Target and Biomarker for Acute Myeloid Leukemia

Target Name: RUNX1

NCBI ID: G861

RUNX1

RUNX1: A Potential Drug Target and Biomarker for Acute Myeloid Leukemia

Abstract:

Acute myeloid leukemia (AML) is a type of cancer that affects the bone marrow and blood cells. It is a serious and often fatal disease, with high treatment rates and a poor prognosis. Despite advances in cancer treatment, the survival rate for AML remains poor, and there is a high demand for more effective and targeted therapies. In this article, we discuss the protein RUNX1 and its potential as a drug target and biomarker for AML.

Introduction:

AML is a type of cancer that affects the bone marrow and blood cells. It is characterized by the overproduction of white blood cells, particularly leukemia cells. AML is a serious and often fatal disease, with high treatment rates and a poor prognosis. Despite advances in cancer treatment, the survival rate for AML remains poor, and there is a high demand for more effective and targeted therapies.

RUNX1: A Potential Drug Target:

RUNX1 is a protein that is expressed in a variety of tissues, including the bone marrow, spleen, and lymph nodes. It is characterized by the presence of a single exon in its gene and its ability to form a monomeric complex with other proteins. RUNX1 has been shown to play a role in the development and progression of AML.

Studies have shown that overexpression of RUNX1 is associated with the development of AML. Additionally, inhibition of RUNX1 has been shown to be a potential therapeutic approach for AML. Several studies have shown that inhibiting RUNX1 with small molecule inhibitors can induce apoptosis (programmed cell death) in AML cells, leading to a reduction in the number of leukemia cells.

RUNX1 as a Biomarker:

RUNX1 can also be used as a biomarker for AML. The expression of RUNX1 has been shown to be associated with the severity of AML, with higher expression levels being associated with more severe disease. Additionally, studies have shown that RUNX1 levels can be used as a predictor of AML outcomes, with higher levels of RUNX1 being associated with a poor prognosis.

Conclusion:

In conclusion, RUNX1 is a protein that has been shown to play a role in the development and progression of AML. Its overexpression is associated with the development of AML, and inhibition of RUNX1 with small molecule inhibitors has been shown to be a potential therapeutic approach for AML. Additionally, RUNX1 can be used as a biomarker for AML, with higher expression levels of RUNX1 being associated with more severe disease and a poor prognosis. Further research is needed to fully understand the role of RUNX1 in AML and its potential as a drug target and biomarker.

Protein Name: RUNX Family Transcription Factor 1

Functions: Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (Probable). Essential for the development of normal hematopoiesis (PubMed:17431401). Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter (PubMed:10207087, PubMed:14970218). Inhibits KAT6B-dependent transcriptional activation (By similarity). Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity). Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells (PubMed:17377532). Positively regulates the expression of RORC in T-helper 17 cells (By similarity)

The "RUNX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RUNX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets